Von Hoff DD, Layard MW, Basa P., et al: Risk factors for doxorubicin-induced congestive heart failure . Ann Intern Med91:710-717, 1979
2.
Von Hoff DD, Rozencweig M., Layard MW, et al: Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases. Am J Med62:200-208, 1977
3.
Myers CE, Chabner BA: Anthracyclines, in Chabner BA, Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 356-381
4.
Sallan SE, Clavell LA: Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: A 10-year experience. Semin Oncol11:19-21, 1984
5.
Lipschultz SE , Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood . N Engl J Med324:808-815, 1991
6.
Legha S., Benjamin RS, Mackay B., et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med96:133-139, 1982
7.
Speyer JL, Green MD, Kramer E., et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiotoxicity in women with advanced breast cancer. N Engl J Med319:745-752, 1988
8.
Hochster H., Wasserheit C., Speyer J.: Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol7:304-309, 1995
9.
Gianni L., Myers CE: The role of free radical formation in the cardiotoxicity of anthracyclines , in Muggia F, Green M, Speyer J (eds): Cancer Treatment and the Heart. Baltimore, MD, The Johns Hopkins University Press, 1992, p 173-197
10.
Physicians Desk Reference (ed 50). Oradell, NJ, Medical Economics Company Inc, 1996, pp 1961-1963
11.
Wexler L., Berg S., Andrich M., et al: ICRF-187 reduces doxorubicin-induced cardiotoxicity with no impact on response to chemotherapy. Proc Am Soc Clin Oncol12:413, 1993 (abstr)
